| Stage | LLY | % of rev | PBYI | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $24.4B | 100.00% | $57M | 100.00% | LLY ×431.79 |
| Gross profit | $20.5B | 83.88% | $44M | 77.92% | LLY +6.0pp |
| Operating income | $8.6B | 35.28% | $8M | 13.42% | LLY +21.9pp |
| Pre-tax income | $8.4B | 34.46% | $8M | 14.59% | LLY +19.9pp |
| Net income | $6.5B | 26.44% | $8M | 14.49% | LLY +11.9pp |
| Stage | LLY | PBYI | Gap · A − B |
|---|---|---|---|
| Revenue | $24.4B100.00% | $57M100.00% | LLY ×431.79 |
| Gross profit | 83.88%$20.5B | 77.92%$44M | LLY +6.0pp |
| Operating income | 35.28%$8.6B | 13.42%$8M | LLY +21.9pp |
| Pre-tax income | 34.46%$8.4B | 14.59%$8M | LLY +19.9pp |
| Net income |
| 26.44%$6.5B |
| 14.49%$8M |
| LLY +11.9pp |
LLY 10-KFeb 12 '26
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue.”
PBYI 10-KFeb 26 '26
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.”
LLY 10-KFeb 12 '26
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue.”
PBYI 10-KFeb 26 '26
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.”